Spinal Stimulation + 5-Azacitidine for Cerebral Palsy

This trial explores how spinal stimulation can improve movement in children with Cerebral Palsy, a condition affecting muscle control. The program lasts 16 weeks and includes weekly sessions of spinal stimulation and activity-based training. Some participants may also receive 5-Azacitidine, a chemotherapy drug, to assess its potential to further enhance mobility. Children with Cerebral Palsy, including those with spastic hemiplegia or diplegia who can perform simple tasks with assistance, might be suitable for this trial. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, contributing to significant advancements in therapy.

The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss this with the trial investigator or your doctor.

A previous study demonstrated that transcutaneous spinal cord stimulation (tSCS) is safe and well-tolerated in both adults and children. This non-invasive method sends electrical pulses to the skin over the spinal cord. Participants in various studies have generally handled the stimulation without serious side effects. For instance, one study involving children with spinal cord injuries reported that all participants managed the treatment well.

Conversely, 5-Azacitidine, also known as Vidaza, is a drug used for certain blood disorders. In a study with children who had relapsed blood conditions, a dose of 75 mg/m² of 5-Azacitidine proved to be safe. However, its safety for treating conditions like cerebral palsy remains under investigation. Some research has suggested possible benefits, but more studies are needed to fully understand its effects in this new context.

Researchers are excited about the combination of transcutaneous spinal cord stimulation (tSCS) and 5-Azacitidine for cerebral palsy because it offers a novel approach to improving motor function. Unlike traditional therapies that focus on physical rehabilitation alone, this treatment combines electrical stimulation to enhance neural pathways with 5-Azacitidine, a drug that may modify gene expression to further aid in recovery. This dual approach could provide more comprehensive improvements in mobility for individuals with cerebral palsy, particularly those with more severe motor impairments. The potential for tSCS to work in synergy with 5-Azacitidine represents a significant advancement over conventional therapies that do not address underlying biological mechanisms.

Studies have shown that transcutaneous spinal cord stimulation (tSCS) can improve movement in children with cerebral palsy. Some children have experienced better walking coordination and reduced fatigue after tSCS therapy. Research also indicates that this treatment can significantly reduce muscle stiffness. In this trial, one group of participants will receive tSCS combined with functional activity training. Another group will receive tSCS with functional activity training and 5-Azacitidine, a drug originally used for cancer, now studied for its potential to reduce muscle tightness in cerebral palsy. Early results suggest it might enhance movement when combined with other treatments. Together, these therapies aim to help children with cerebral palsy move better and experience less muscle stiffness.¹⁶⁷⁸⁹